Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 2/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.55 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.55 |
| ▸ | GNAI3 | P08754 | 9/20 | 0.49 |
| ▸ | GNAI1 | P63096 | 9/20 | 0.49 |
| ▸ | GNAO1 | P09471 | 8/20 | 0.49 |
| ▸ | F2R | P25116 | 1/20 | 0.46 |
| ▸ | NAAA | Q02083 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4133265 | 0.92 | BCHE (0.56) | BCHEMEN1KMT2AL3MBTL1TDP1 | |
| SCHEMBL4141741 | 0.88 | BCHE (0.64) | BCHEMEN1KMT2AL3MBTL1TDP1 | |
| SCHEMBL10535920 | 0.85 | MEN1 (0.61) | MEN1KMT2AL3MBTL1TDP1POLB | |
| SCHEMBL10755546 | 0.85 | MEN1 (0.61) | MEN1KMT2AL3MBTL1TDP1POLB | |
| SCHEMBL10535711 | 0.85 | MEN1 (0.61) | MEN1KMT2AL3MBTL1TDP1POLB | |
| SCHEMBL10534671 | 0.85 | MEN1 (0.61) | MEN1KMT2AL3MBTL1TDP1POLB | |
| SCHEMBL10535723 | 0.85 | MEN1 (0.61) | MEN1KMT2AL3MBTL1TDP1POLB | |
| SCHEMBL10772526 | 0.85 | MEN1 (0.61) | MEN1KMT2AL3MBTL1TDP1POLB | |
| SCHEMBL9427708 | 0.85 | MEN1 (0.61) | MEN1KMT2AL3MBTL1TDP1POLB | |
| SCHEMBL4131718 | 0.84 | ITGB3 (0.56) | BCHEMEN1KMT2AL3MBTL1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090192192-A1 | INHIBITORS OF BIOFILM FORMATION OF GRAM-POSITIVE AND GRAM-NEGATIVE BACTERIA | TOUCH BIONICS LIMITED (GB) | 2009-07-30 | — | — | US | disclosed |
| US-20090192192-A1 | INHIBITORS OF BIOFILM FORMATION OF GRAM-POSITIVE AND GRAM-NEGATIVE BACTERIA | TOUCH BIONICS LIMITED (GB) | 2009-07-30 | — | — | US | disclosed |
| US-20090192192-A1 | INHIBITORS OF BIOFILM FORMATION OF GRAM-POSITIVE AND GRAM-NEGATIVE BACTERIA | TOUCH BIONICS LIMITED (GB) | 2009-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192192-A1 | INHIBITORS OF BIOFILM FORMATION OF GRAM-POSITIVE AND GRAM-NEGATIVE BACTERIA | PGLS, TFPI, Q6ZSR9 | BCHE 2865/4885MEN1 4659/4885KMT2A 3636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.